Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why Lamassu Pharma is developing a novel pancreatitis treatment

While several attempts to develop drugs for severe acute pancreatitis have failed, Lamassu's RABI-767 could offer a unique approach to treating the disease.

By Brian Buntz | August 24, 2021

Lamassu PharmaAcute pancreatitis, involving a sudden inflammation of the pancreas, is a major unmet need in gastroenterology. Severe cases can land patients in the ICU for weeks or months, while treatment options are relegated to support. The condition causes approximately 330,000 hospital admissions annually, according to a 2018 study. Some 20,000 people in the U.S. die from the disease each year. 

Lamassu Pharma (Durham, N.C.) is developing a drug known as RABI-767 that could offer hope to patients with severe acute pancreatitis. The company is gearing up for a Phase 1 trial for the drug. 

Initially discovered by the Mayo Clinic, RABI-767 is a small molecule lipase inhibitor and Lamassu’s lead candidate. After Mayo performed several experiments on the drug candidate, Lamassu moved swiftly to license it. “We kind of went zero to 100 in two seconds,” said Dr. Gabi Hanna, CEO of the company. 

[Related: Prioritizing translational research is changing drug development for patients and doctors, for good]

Offering a treatment option for patients with severe acute pancreatitis could have a sizable impact, Hanna said. At present, physicians treating severe forms of the disease tend to focus on providing oxygenation and fluids while keeping tabs on necrosis and the function of other organs. “Kidney failure is very common,” Hanna said. 

RABI-767 is grounded in “a unique scientific approach,” Hanna said. For one thing, the drug would be delivered via intraperitoneal (IP) injection in the abdomen. The drug delivery method may be “very untraditional,” Hanna acknowledged, but it could protect the tissue around the pancreas and prevent enzymes within it from causing damage to other parts of the body. 

“You don’t want enzymes that are responsible for digesting meat to start digesting your body,” Hanna said. 

When the pancreas is inflamed, and blood vessels within it are damaged, it is difficult for a drug in the bloodstream to penetrate it. Such considerations led to the idea of IP injection. 

Dr. Gabi Hanna

Dr. Gabi Hanna

“We got a lot of pushback regarding IP injection,” Hannah acknowledged. “The traditional wisdom in pharma often is, ‘You shouldn’t be the first to try something new,’” he said. “Be we decided to stick with the science and increase the chances of success rather than follow an established path.”

Hanna envisions that interventional radiologists would administer the drug via GI endoscopy or by informing drug delivery with CT or ultrasound to “deliver the drug to a targeted area very accurately,” Hanna said. 

In preclinical studies, RABI-767 reduced the breakdown or release of unsaturated and saturated fats in acute pancreatitis attacks. Rapid breakdown of unsaturated fat can exacerbate acute pancreatitis. 

While the company is currently focused on RABI-767, in time, it could become “more of a portfolio company,” Hanna said. That approach is hinted at in the company’s name. “Lamassu” refers to a mythological hybrid of a human, lion, eagle and bull. Similarly, “we envisioned having multiple assets — bringing the best science from each indication together,” Hanna said. 


Filed Under: Gastroenterology
Tagged With: acute pancreatitis, intraperitoneal, Lamassu Pharma, RABI-767
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Austrian researchers find IgA-tagged vesicles turn gut’s own antibodies against it, worsening ulcerative colitis
One of C. difficile’s metabolic powers might be turning a toxin into a fuel
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly’s FDA approval for Omvoh close up: Nearly 90% of one-year responders maintained remission through two years
Lumen Bioscience
How an engineered algae-based biologic aims to break the annual $5B cycle of c. diff reinfection
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE